This is a Phase 1 Study in Which Healthy Volunteers and Participants with Chronic HBV Infection Will Receive HT-101 or Placebo and Will Be Assessed for Safety, Tolerability, Pharmacokinetics (PK), and Antiviral Activity

Name: This is a Phase 1 Study in Which Healthy Volunteers and Participants with Chronic HBV Infection Will Receive HT-101 or Placebo and Will Be Assessed for Safety, Tolerability, Pharmacokinetics (PK), and Antiviral Activity
Published: 2022
License: Public Domain

Suzhou HepaThera Biotech Co., Ltd. · 2022

ClinicalTrials.gov · Datasets · License: Public Domain · 2022

Open Source ↗

chronic hepatitis b, interventional, phase1

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

This is a Phase 1 Study in Which Healthy Volunteers and Participants with Chronic HBV Infection Will Receive HT-101 or Placebo and Will Be Assessed for Safety, Tolerability, Pharmacokinetics (PK), and Antiviral Activity

Related documents